LQDA
Liquidia Corporation
There isn't enough reported data to score LQDA yet.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
LQDA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Strong | |
| Strong |
LQDA's revenue, cash flow and balance sheet are currently healthy, but its profitability is under pressure.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
LQDA PE Valuation
LQDA has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
LQDA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Strong growth | |
| Strongly weakening | |
| Limited | |
| Low |
LQDA has the edge over NVO on the outlook, with more favorable earnings expectations.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
LQDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.15 | — |
| Q3 2026 | -$1.20 | +$0.23 |
| Q2 2026 | $1.40 | +$3.09 |
| Q1 2026 | $0.17 | +$1.74 |
| Q4 2025 | -$0.80 | +$0.86 |
| Q3 2025 | -$1.43 | +$0.21 |
| Q2 2025 | -$1.69 | -$0.11 |
| Q1 2025 | -$1.57 | $0.00 |
| Q4 2024 | -$1.66 | -$0.45 |
LQDA is still losing money, but far less than before: $1.20 per share over the past year, against $2.60 at its worst in late 2019.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over LQDA on earnings quality, reporting a profit while its opponent remains loss making.
LQDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $225.3M | +315% |
| Q2 2026 | $171.7M | +1843% |
| Q1 2026 | $132.9M | +4158% |
| Q4 2025 | $92M | +3055% |
| Q3 2025 | $54.3M | +1122% |
| Q2 2025 | $8.8M | +142% |
| Q1 2025 | $3.1M | +5% |
| Q4 2024 | $2.9M | -36% |
LQDA has the edge over NVO on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -117% | -120 points |
| Q2 2026 | 50% | +474 points |
| Q1 2026 | 46% | +1182 points |
| Q4 2025 | 22% | +1259 points |
| Q3 2025 | 3.3% | +660 points |
| Q2 2025 | -424% | +319 points |
| Q1 2025 | -1135% | -166 points |
| Q4 2024 | -1238% | -654 points |
LQDA's operating margin was −117% last quarter, down 120 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over LQDA on profitability, with a higher operating margin.
LQDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $129.8M | +$140.5M |
| Q2 2026 | $69M | +$109.5M |
| Q1 2026 | $50.2M | +$81.2M |
| Q4 2025 | $42.2M | +$64.3M |
| Q3 2025 | -$10.7M | +$16.1M |
| Q2 2025 | -$40.5M | -$16.6M |
| Q1 2025 | -$31M | -$5.5M |
| Q4 2024 | -$22.1M | -$5.9M |
LQDA's free cash flow has turned positive after six years mostly in the red: $291M over the past year.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
LQDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -12% | -11.9M shares |
| 1 year | +3.7% | +3.2M shares |
| 3 years | +38% | +24.7M shares |
| 5 years | +72% | +37.4M shares |
| Available history | +340% | +69.2M shares |
LQDA has 90M diluted shares, up 3.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over LQDA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
LQDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -1.7x | Net Cash |
| Q1 2026 | -4.8x | Net Cash |
LQDA has the edge over NVO on leverage, with a lower net debt burden relative to earnings.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
LQDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 52.2 | Neutral |
| Stochastic | 37.7 | Neutral |
LQDA's weekly RSI is 52 (neutral) and its Stochastic is 38 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
LQDA PE vs Healthcare Sector
| Metric | LQDA | Sector median | Relative |
|---|---|---|---|
| PE | 32x | 26x | 23% above |
| PE % | 16 | 29 | 13 pts below |
LQDA has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over LQDA on valuation relative to its sector.
LQDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $43.6 | 33% above |
| 20 week MA | $63.0 | 7.7% below |
| 50 week MA | $51.4 | 13% above |
| 100 week MA | $34.9 | 67% above |
| 200 week MA | $22.3 | 160% above |
LQDA has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
LQDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.94 | $2.82 | -43% |
| 2021 | $2.82 | $4.67 | +66% |
| 2022 | $4.67 | $6.17 | +32% |
| 2023 | $6.17 | $12.0 | +95% |
| 2024 | $12.0 | $11.6 | -3.8% |
| 2025 | $11.6 | $34.4 | +197% |
| 2026 YTD | $34.4 | $58.1 | +69% |
LQDA has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.